Pentetic Acid
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Pentetic Acid: From Diagnostic Imaging Agent to Thrombocytopenic Purpura
One-Sentence Summary
Pentetic acid (DTPA) is a metal-chelating agent, registered in Singapore as a kit for preparing radiopharmaceuticals (Technescan DTPA for Injection). The TxGNN model predicts it may be effective for thrombocytopenic purpura, but no clinical trials and no publications currently support this prediction. It is a model-only signal at this stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore registration data |
| Predicted New Indication | Thrombocytopenic purpura |
| TxGNN Prediction Score | 97.25% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, pentetic acid (DTPA) is a chelating agent used mainly as a carrier for radiopharmaceuticals (for example, Tc-99m DTPA renal and lung imaging) and for metal decorporation. Its approved use is diagnostic rather than therapeutic.
No plausible mechanism links DTPA to platelet disorders. The score of 0.972 is a network-based model prediction without supporting trial or literature data, so it should not be read as evidence of efficacy.
Other predictions for this drug (all with scores of about 0.956–0.967 and no supporting studies) were also reviewed:
- Idiopathic copper-associated cirrhosis (score 96.0%) is the most biologically plausible candidate. DTPA binds polyvalent metals, and copper chelation is the established principle in copper overload disorders such as Wilson disease. However, DTPA is not a standard copper chelator (penicillamine and trientine are). A preclinical copper-binding and hepatic safety assessment would be a reasonable first step.
- Hepatic porphyria (96.7%) has only a speculative link through metal effects on heme synthesis.
- The remaining candidates (benign recurrent intrahepatic cholestasis, early-onset familial noncirrhotic portal hypertension, hepatopulmonary syndrome, primitive portal vein thrombosis, hepatoportal sclerosis, peliosis hepatis, hepatic infarction) have no identifiable mechanistic rationale. Many scores appear to reflect network proximity among liver disorders rather than pharmacology.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN12150P | Technescan DTPA for Injection 20.8 mg/vial (Curium Netherlands B.V.) | Injection, powder, for solution | Not stated in the registration data |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on the TxGNN model (Level L5). There are no clinical trials or publications, and no plausible mechanism links DTPA to thrombocytopenic purpura. The current product is a diagnostic kit, not a therapeutic agent.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA, which are required before any safety screening
- Mechanism of action data, to allow a proper mechanistic analysis
- Confirmation of the approved indication for the Singapore registration
- A literature and trial search specific to the predicted indications
- For the copper-associated cirrhosis lead, preclinical or in vitro copper-binding and hepatic safety assessment, as a research question rather than a development decision
- Assessment of route compatibility, since the only available form is injectable
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.